Tissue Distribution of Indinavir Administered as Solid Lipid Nanocapsule Formulation in mdr1a (+/+) and mdr1a (−/−) CF-1 Mice
- 176 Downloads
Due to protease inhibitor (PI) efflux transport by P-glycoprotein (P-gp), insufficient PI concentrations result in low ongoing HIV replication in the so-called virus sanctuaries (brain and testes). The aim of the present study was to evaluate indinavir-loaded nanocapsules (Ind-LNC) including Solutol® HS15, an excipient reported to possess in vitro P-gp inhibiting properties, as a means to improve indinavir distribution into brain and testes of mice.
Normal mdr1a (+/+) or P-gp-deficient mdr1a (−/−) CF-1 mice were dosed with Ind-LNC (10 mg indinavir/kg, i.v.). At 30 min postadministration, indinavir was determined in plasma, brain, testes, as well as in kidneys, liver, and heart by LC-MS/MS, and tissue/plasma concentration ratios were calculated. Results were compared with those of control groups that received an indinavir solution (Ind-Sol).
Using Ind-Sol, ratios were 21.3- and 3.3-fold higher in brains and testes of mdr1a (−/−) mice than of mdr1a (+/+) mice, respectively, whereas in the other organs ratios were not significantly different between the two substrains. When Ind-LNC was used, a similar [mdr1a (−/−) vs. mdr1a (+/+) mice] trend was observed. Moreover, ratios were found to be significantly increased (1.9-fold increase in average) in most organs (brain and testes in particular) with Ind-LNC compared to Ind-Sol, regardless of the substrain used.
In agreement with previous works, P-gp governs at least in part indinavir uptake into brain and testes. LNC formulation increased indinavir uptake in brain and testes by mechanisms other than, or additional to, P-gp inhibition.
Key WordsCF-1 mice indinavir P-glycoprotein solid lipid nanocapsule Solutol® HS15
indinavir-loaded lipid nanocapsules
We are grateful for the excellent technical assistance of Mrs. Isabelle Lamarche.
- 16.B. Heurtault, P. Saulnier, B. Pech, J. E. Proust, J. Richard, J. P. Benoit. A novel phase inversion-based process for the preparation of lipidic nanocarriers, 2000. Patent FR 0002688.Google Scholar
- 21.Li, L. Y., Amidon, G. L., Kim, J. S., Heimbach, T., Kesisoglou, F., Topliss, J. T., Fleisher, D. 2002Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in ratJ. Pharmacol. Exp. Ther.301586593CrossRefPubMedGoogle Scholar
- 22.Tse, F. L. S. 1995
Pharmacokinetics in drug discovery and development: nonclinical studiesWelling, P. G.Tse, F. L. S. eds. Pharmacokinetics: Regulatory, Industrial, Academic Perspectives2Marcel DekkerNew York281334Google Scholar
- 23.Wu, E. Y., Wilkinson, J. M., Naret, D. G., Daniels, V. L., Williams, L. J., Khalil, D. A., Shetty, B. V. 1997High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasmaJ. Chromatogr. B Biomed. Sci. Appl.695373380CrossRefPubMedGoogle Scholar
- 24.Heeswijk, R. P., Hoetelmans, R. M., Harms, R., Meenhorst, P. L., Mulder, J. W., Lange, J. M., Beijnen, J. H. 1998Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detectionJ. Chromatogr. B Biomed. Sci. Appl.719159168PubMedGoogle Scholar
- 32.Schinkel, A. H., Mayer, U., Wagenaar, E., Mol, C. A., Deemter, L., Smit, J. J., Valk, M. A., Voordouw, A. C., Spits, H., Tellingen, O., Zijlmans, J. M., Fibbe, W. E., Borst, P. 1997Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteinsProc. Natl. Acad. Sci. USA9440284033CrossRefPubMedGoogle Scholar
- 42.Komarov, P. G., Shtil, A. A., Buckingham, L. E., Balasubramanian, M., Piraner, O., Emanuele, R. M., Roninson, I. B., Coon, J. S. 1996Inhibition of cytarabine-induced MDR1 (P-glycoprotein) gene activation in human tumor cells by fatty acid–polyethylene glycol–fatty acid diesters, novel inhibitors of P-glycoprotein functionInt. J. Cancer68245250CrossRefPubMedGoogle Scholar